このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Adagene マネジメント

マネジメント基準チェック /14

Adagene'sの CEO はPeizhi Luoで、 Nov2011年に任命され、の在任期間は 12.58年です。は、会社の株式の3.26%を直接所有しており、その価値は$ 3.61M 。経営陣と取締役会の平均在任期間はそれぞれ5.7年と2.6年です。

主要情報

Peizhi Luo

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	12.8yrs
CEOの所有権	3.3%
経営陣の平均在職期間	6yrs
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

CEO（最高経営責任者

Peizhi Luo (58 yo)

12.8yrs

在職期間

Dr. Peter P. Luo, PhD, also known as Peizhi, is the Founder of Adagene Inc. and serves as its Chief Executive Officer since November 2011 and Director since February 2018. He serves as President of R&D at...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Peter P. Luo	Co- Founder	12.8yrs	データなし	3.25% $ 3.2m
Man Kin Tam	CFO & Director	5yrs	データなし	データなし
Jc Xu	Chief Scientific Officer	4.1yrs	データなし	データなし
Ami Knoefler	Vice President of Investor Relations & Corporate Communications	no data	データなし	データなし
Ling Zhou	Head of Human Resources	4.9yrs	データなし	データなし
Qinghai Zhao	Chief Manufacturing Officer	3.9yrs	データなし	データなし
Yan Li	Senior Vice President of Bioinformatics & Information Technology	12.8yrs	データなし	データなし
Xiaohong She	Senior VP & Head of Clinical Operations	12.8yrs	データなし	0.094% $ 93.5k
Guizhong Liu	Senior Vice President of Early Drug Discovery	8.9yrs	データなし	データなし
Alexander Goergen	VP & Head of Business Development	6.9yrs	データなし	データなし
Jiping Zha	Executive Vice President of Clinical Development	2.9yrs	データなし	データなし
Songmao Zheng	VP and Head of Clinical & Quantitative Pharmacology	no data	データなし	データなし

6.0yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ADAGの経営陣は経験豊富で経験豊富です（平均在職期間は5.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Peter P. Luo	Co- Founder	6.6yrs	データなし	3.25% $ 3.2m
Man Kin Tam	CFO & Director	3.6yrs	データなし	データなし
Li Zhu	Independent Director	1.1yrs	データなし	データなし
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	3.1yrs	データなし	データなし
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	3.1yrs	データなし	データなし
Mervyn J. Turner	Independent Director	1.4yrs	データなし	データなし
Cuong Viet Do	Independent Director	1.8yrs	データなし	データなし
David R. Gandara	Member Scientific & Strategic Advisory Board	2.7yrs	データなし	データなし
Yumeng Wang	Director	1.4yrs	データなし	データなし
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	1.5yrs	データなし	データなし
Yiu Leung Cheung	Independent Director	3.6yrs	データなし	データなし
Stanley Frankel	Member Scientific & Strategic Advisory Board	3.1yrs	データなし	データなし

2.9yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: ADAGの取締役会は経験豊富ではない ( 2.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Adagene マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Adagene Inc. Announces Board and Management Changes

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14